What is Supernus Pharmaceuticals's AOCI?

Supernus Pharmaceuticals (SUPN) reported AOCI of -$255K in Q1 2026.

How has Supernus Pharmaceuticals's AOCI changed year-over-year?

Supernus Pharmaceuticals's AOCI decreased by 60.4% year-over-year, from -$159K to -$255K.

What is the long-term trend for Supernus Pharmaceuticals's AOCI?

Over 5 years (2020 to 2025), Supernus Pharmaceuticals's AOCI has grown at a -65.5% compound annual growth rate (CAGR), from $8.98M to -$44K.

Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Supernus Pharmaceuticals SUPN AOCI

AOCI at other companies

AbbVieABBV

-$1.15B+33.8%

Rapport Therapeutics, Inc.RAPP

-$505K-432%

Neurocrine BiosciencesNBIX

$400K-95.6%

Jazz PharmaceuticalsJAZZ

-$651M+17.1%

Acadia PharmaceuticalsACAD

-$563K-229%

Catalyst PharmaceuticalCPRX

$8K+147%

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's AOCI?: Supernus Pharmaceuticals (SUPN) reported AOCI of -$255K in Q1 2026.
How has Supernus Pharmaceuticals's AOCI changed year-over-year?: Supernus Pharmaceuticals's AOCI decreased by 60.4% year-over-year, from -$159K to -$255K.
What is the long-term trend for Supernus Pharmaceuticals's AOCI?: Over 5 years (2020 to 2025), Supernus Pharmaceuticals's AOCI has grown at a -65.5% compound annual growth rate (CAGR), from $8.98M to -$44K.
What does AOCI mean?: Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.